statementSaid on 2026-11-11

The self-developed SHR-3201 injection has been approved by the National Medical Products Administration to conduct clinical trials, and it is intended for Alzheimer's disease.

A statement by post author, said on 2026-11-11. Statements are as reported by the cited publishers — not verified by DecisionGateway.

自主研發的SHR-3201注射液已獲國家藥監局批准開展臨床試驗,擬用於阿爾茨海默病
stockintelligencenewsPublished 2026-11-11 Read source

Discussion

0/2000